GlassScriptPhysician profile
Katherine Lois Stuart
NPI 1679060198
$6,509.86
in general payments reported to CMS, 2019-2025
49 companies · $1,242 in 2025
The $1,242 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $326 · 2022: $1,120 · 2023: $1,892 · 2024: $1,930 · 2025: $1,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,063.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $704.81 | 2021-2025 | |
| Pfizer INC. | $459.16 | 2023-2025 | |
| Ucb, INC. | $448.94 | 2023-2025 | Zilbrysq, Briviact, Rystiggo |
| Novartis Pharmaceuticals Corporation | $432.77 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $393.89 | 2022-2025 | Ultomiris |
| Lundbeck LLC | $358.88 | 2023-2025 | Vyepti, Rexulti |
| Biogen, INC. | $285.36 | 2022-2025 | Vumerity, Skyclarys, Tysabri |
| Sk Life Science, INC. | $278.36 | 2023-2025 | |
| Amgen INC. | $231.23 | 2021-2022 | |
| Argenx US, INC. | $230.81 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Eisai INC. | $200.40 | 2023-2025 | |
| Lilly USA, LLC | $193.87 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Acadia Pharmaceuticals INC | $186.58 | 2024-2025 | Nuplazid |
| Acorda Therapeutics, INC | $183.63 | 2022-2024 | Inbrija |
| Csl Behring | $162.31 | 2022-2024 | Hizentra |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Stuart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.